Row herosectionWave Shape Decorative svg added to bottom

Events Genome Engineering: CRISPR Frontiers 2026

Genome Engineering: CRISPR Frontiers

August 11-15, 2026

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Join MaxCyte at CRISPR Frontiers 2026 for a luncheon seminar on genomic safety assessment for base editing therapeutics and evolving FDA expectations.

You're Invited to a MaxCyte Luncheon Seminar at Genome Engineering: CRISPR Frontiers 2026

Note: You must register for the Cold Spring Harbor Conference, Genome Engineering: CRISPR Frontiers to attend the workshop

Date: Wednesday, August 12, 2026
Time: Following the morning session
Location: Cold Spring Harbor Laboratory – Plimpton Conference Room / Beckman Building

Base editor genomic safety assessment: keeping pace with emerging FDA expectations

Join us for an engaging lunch-hour workshop designed for gene editing researchers interested in the latest approaches to genomic safety assessment for base editing therapeutics. This session will explore a comprehensive, regulatory-aligned framework for evaluating off-target activity and structural genomic alterations, supporting the development of safer gene editing therapies.

Led by our expert scientists, this session will:

  • Present a regulatory-aligned framework for genomic safety assessment of base editing therapeutics

  • Explore complementary approaches for genome-wide off-target site nomination using ONE-seq and CHANGE-seq

  • Explain how the SeQure™ Edits of Relative Concern (ERC) framework prioritizes candidate off-target sites based on genomic and functional annotations

  • Review highly sensitive targeted sequencing methods for confirming off-target editing in relevant cell types and tissues

  • Highlight approaches for detecting structural rearrangements, including translocations and deletions, using SAFER detection

  • Demonstrate how these complementary technologies work together to support comprehensive genomic safety assessment and IND-enabling therapeutic development.

Whether you're developing or evaluating base editing therapeutics, this workshop will provide practical insights into integrating complementary off-target nomination, confirmation, and structural rearrangement analyses into a comprehensive genomic safety assessment workflow.

Lunch will be provided. Seating is limited—reserve your spot early!

Speakers

Bob Headshot

Bob Policastro, PhD

Bioinformatics Manager, MaxCyte, Inc.

Bob Policastro is the Bioinformatics Manager at MaxCyte/SeQure, where he bolsters the company's computational offerings to support clients in off-target assessment for cell and gene therapy programs. Prior to MaxCyte, he served as Head of Computational Biology at Ensoma, a clinical-stage in vivo cell and gene therapy startup. He began his biotech career at eGenesis, a clinical-stage company developing gene-edited porcine organs for xenotransplantation into humans. Bob received his PhD from Indiana University Bloomington, where his research focused on next-generation sequencing method development and the genomics of transcriptional regulation.

Register below to attend this event

Popular resources

maxcyte-enables-a-cgmp-compatible-manufacturing-process-for-highly-efficient-t-cell@2x-min
application note
MaxCyte® Enables a cGMP-Compatible Manufacturing Process for Highly Efficient T Cell Engineering
Conditional-Deletion-of-Large-DNA-Fragment-in-iPSCs-by-ssODN-Mediated-Insertion-of-LoxP-Sites-without-Antibiotic-Selection-Fig-2 1
Scientific Brief
Gene Editing: Paving the Way for Accelerated Clinical Development of Adoptive Cell Therapies
Experimental-Design-hires 1
Scientific Brief
Conditional Deletion of Large DNA Fragment in iPSCs by ssODN-Mediated Insertion of LoxP Sites without Antibiotic Selection
View All Resources